Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice
Eiki Takimoto, … , Michael E. Mendelsohn, David A. Kass
Eiki Takimoto, … , Michael E. Mendelsohn, David A. Kass
Published January 5, 2009
Citation Information: J Clin Invest. 2009;119(2):408-420. https://doi.org/10.1172/JCI35620.
View: Text | PDF
Research Article Cardiology

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

  • Text
  • PDF
Abstract

The heart initially compensates for hypertension-mediated pressure overload by enhancing its contractile force and developing hypertrophy without dilation. Gq protein–coupled receptor pathways become activated and can depress function, leading to cardiac failure. Initial adaptation mechanisms to reduce cardiac damage during such stimulation remain largely unknown. Here we have shown that this initial adaptation requires regulator of G protein signaling 2 (RGS2). Mice lacking RGS2 had a normal basal cardiac phenotype, yet responded rapidly to pressure overload, with increased myocardial Gq signaling, marked cardiac hypertrophy and failure, and early mortality. Swimming exercise, which is not accompanied by Gq activation, induced a normal cardiac response, while Rgs2 deletion in Gαq-overexpressing hearts exacerbated hypertrophy and dilation. In vascular smooth muscle, RGS2 is activated by cGMP-dependent protein kinase (PKG), suppressing Gq-stimulated vascular contraction. In normal mice, but not Rgs2–/– mice, PKG activation by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardiac hypertrophy, inhibiting Gq-coupled stimuli. Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both genotypes, but PKG plasma membrane translocation was more transient in Rgs2–/– myocytes than in controls and was unaffected by PDE5 inhibition. Thus, RGS2 is required for early myocardial compensation to pressure overload and mediates the initial antihypertrophic and cardioprotective effects of PDE5 inhibitors.

Authors

Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass

×

Figure 1

Cardiac phenotype of Rgs2–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Cardiac phenotype of Rgs2–/– mice.
   
(A) Myocyte RGS2 protein expressi...
(A) Myocyte RGS2 protein expression was detected in Rgs2+/+ (+/+) cells, but not Rgs2–/– (–/–) cells. (B) Adult mouse myocytes (n = 5 per group) from Rgs2–/– hearts displayed an amplified growth response to ET1, as assessed by radiolabeled leucine incorporation. P value shown is for interaction of genotype and condition (2-way ANOVA). #P < 0.01; ##P < 0.001. (C) Representative whole hearts, H&E-stained cross sections, and summary results for heart weight normalized to tibia length (HW/TL) in Rgs2+/+ and Rgs2–/– hearts subjected to 1 wk TAC. White bar shows data from deceased mice. (D) Kaplan-Meier survival curve showing markedly increased mortality in Rgs2–/– mice subjected to TAC compared with littermate controls. (E) Wet lung weight normalized to body weight (n = 8–13 per group). White bar shows data from deceased mice. (F) Representative Masson’s trichrome staining of the heart section. Blue stain indicates collagen deposition. Scale bars: 100 μm. Also shown are summary quantification results on myocyte diameter and collagen fraction (n = 4 hearts per group; >50 cells per heart; 5–6 sections for fibrosis analysis). *P < 0.05 versus Rgs2+/+ sham; §P < 0.05 versus Rgs2–/– sham; †P < 0.05 versus Rgs2+/+ TAC.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts